Care Models for the Genetic Evaluation of Dilated Cardiomyopathy at Sites of the DCM Consortium.

A systematic needs assessment of the DCM Consortium identified four distinct, highly variable care models for genetic evaluation of dilated cardiomyopathy, revealing that while most sites utilize genetic testing for treatment decisions, the implementation of comprehensive services is hindered by operational and staffing challenges despite a consensus on necessary facilitators like genetic counselors and standardized guidelines.

The Gist

Imagine the heart as a complex, high-performance engine. Sometimes, this engine gets weak and stretches out, a condition doctors call Dilated Cardiomyopathy (DCM). Often, the reason this engine fails is written in the "instruction manual" inside our cells—our DNA.

For a long time, doctors have known that reading this manual (genetic testing) is crucial, but they haven't agreed on how to do it. It's like a group of mechanics trying to fix the same broken engine, but some are using a giant, slow workshop, while others are using a quick roadside kit, and no one has a standard rulebook.

This paper is essentially a group meeting report from the top mechanics (Principal Investigators) of the "DCM Consortium." They gathered to figure out: How are we currently checking these engines? What's working? What's broken?

Here is what they found, broken down into simple terms:

1. The Four Ways They Fix the Engine

The researchers discovered that the 24 different clinics they studied were using four distinct "repair strategies" (care models):

• The "Full-Service Workshop" (Traditional-Synchronous): This is the old-school, all-in-one approach. The patient, the heart doctor, and the genetics expert all meet at the same time. It's thorough, but it takes the most time and feels like a long, heavy meeting.
• The "Drop-Off Service" (Traditional-Asynchronous): Similar to the workshop, but the patient drops off their info, and the experts discuss it later. It's a bit more flexible but still relies on the traditional team structure.
• The "Outsourced Specialist" (Externally Sourced): The clinic doesn't do the genetic work themselves; they send the patient to an outside expert, like mailing the engine to a factory for a specific part check.
• The "DIY Quick-Check" (Physician/APP Conducted): The heart doctor or a nurse practitioner does the genetic check themselves. This is the fastest method (least time per patient), but the study found it was the least liked by the experts because it feels rushed and less thorough.

The Verdict: The experts preferred the "Full-Service" and "Drop-Off" models. They felt these were more reliable and acceptable, even if they took longer. The "DIY Quick-Check" was seen as too risky or incomplete.

2. Why Bother Checking the Manual?

Even though the methods varied, everyone agreed on one thing: The results matter.
Almost 9 out of 10 doctors used the genetic results to make life-or-death decisions.

• The "Airbag" Decision: Should the patient get an Implantable Cardioverter Defibrillator (ICD)? This is like an automatic airbag for the heart that shocks it back to life if it stops.
• The "Engine Swap" Decision: Is the patient a candidate for a heart transplant?

3. The Roadblocks and the Green Lights

The doctors held a "focus group" (a big group chat) to discuss why this isn't happening everywhere yet.

• 🚧 The Roadblocks (Barriers):

  • Not enough staff: They are short on the specialized "genetic mechanics" (genetic counselors).
  • Money issues: It's hard to get paid (reimbursement) for these services.
  • Confusion: Many heart doctors don't realize how important genetics are, or they don't know how to fit it into their busy schedule.

• 🚦 The Green Lights (Facilitators):

  • Having a Specialist: When a genetic counselor is actually sitting on the heart team, things work much better.
  • A Rulebook: The doctors are begging for an official, authoritative guide that says, "Here is exactly how you must check for genetics in DCM."

The Big Takeaway

Right now, checking the genetic "instruction manual" for heart failure is a patchwork quilt—some pieces are big and detailed, others are small and missing. Everyone agrees on why it's important, but they are struggling with how to do it efficiently.

The authors hope that by understanding these different "repair strategies," they can build a universal, scalable blueprint. This would allow any heart clinic, big or small, to easily add genetic testing to their care, ensuring every patient gets the right "airbag" or "engine swap" based on their unique DNA.

Technical Summary

Technical Summary: Care Models for the Genetic Evaluation of Dilated Cardiomyopathy at Sites of the DCM Consortium

1. Problem Statement

Clinical genetic evaluation for patients with Dilated Cardiomyopathy (DCM) is currently under-implemented across healthcare systems, and standardized models of care have not been defined. Despite the known utility of genetic testing in guiding management, there is a lack of consensus regarding how these services should be delivered, who should administer them, and the operational time required. This variability hinders the scalability and consistency of precision medicine approaches for DCM.

2. Methodology

To address these gaps, the DCM Consortium conducted a systematic needs assessment involving 24 Principal Investigators (PIs) from various sites. The study employed a mixed-methods approach:

• Electronic Needs Assessment: Distributed prior to the July 2025 Summer Scientific Symposium, this survey evaluated current care models based on Heart Failure Society of America (HFSA) recommended genetic evaluation components. It collected data on the specific components performed, the personnel responsible, and the time investment per patient.
• Descriptive Statistics: Used to characterize the features of the identified care models.
• Focus Group Discussions: Conducted with PIs to qualitatively explore barriers and facilitators to implementing genetic services.
• Statistical Analysis: Comparative analysis was performed to assess the acceptability ratings of different models.

3. Key Contributions

The study provides the first comprehensive mapping of existing genetic care delivery models for DCM within a major consortium. Key contributions include:

• Taxonomy of Care Models: Identification and classification of four distinct operational models currently in use.
• Quantitative Benchmarking: Establishment of time requirements and acceptability scores for different delivery methods.
• Clinical Impact Data: Documentation of the high frequency with which genetic results influence critical clinical decisions (e.g., ICD placement, transplant listing).
• Strategic Roadmap: Synthesis of operational barriers and facilitators to guide future standardization efforts.

4. Results

A. Identified Care Models
Four distinct models emerged from the 24 sites:

1. Traditional-Synchronous (25%, n=6): Involves real-time interaction; requires the most time per patient.
2. Traditional-Asynchronous (33%, n=8): Involves delayed interaction (e.g., chart review, remote consultation).
3. Externally Sourced (17%, n=4): Relies on outside genetic services.
4. Physician/Advanced Practice Provider (APP) Conducted (25%, n=6): Managed internally by non-geneticist clinicians; requires the least time per patient.

B. Implementation and Acceptability

• Testing vs. Comprehensive Care: While 100% of models utilized genetic testing, other recommended HFSA components (e.g., family screening, counseling) were implemented variably or not at all.
• Acceptability Ratings: Models 1 (15.7 ± 4.1) and 2 (15.4 ± 3.0) were rated significantly more acceptable than Model 4 (9.8 ± 2.9).
  • Statistical Significance: Model 1 vs. Model 4 ($p=0.027$); Model 2 vs. Model 4 ($p=0.023$).
• Clinical Utility: Genetic information heavily influences treatment decisions:
  • 88% of PIs use results for treatment planning.
  • 83% (n=20) utilize results for Implantable Cardioverter-Defibrillator (ICD) placement decisions.
  • 63% (n=15) utilize results for cardiac transplant evaluation.

C. Barriers and Facilitators

• Facilitators: Presence of a dedicated genetic counselor on the Heart Failure team and the development of authoritative standards for service provision.
• Barriers: Operational challenges, personnel shortages, lack of clinician recognition of genetic needs, the necessity for new service delivery models, and issues regarding billing/reimbursement.

5. Significance

This study highlights a critical disconnect between the high clinical utility of DCM genetic testing and the lack of standardized, scalable delivery models. The findings suggest that while sites are eager to use genetic data for life-saving interventions (ICD/Transplant), the current reliance on variable, often time-intensive models (or under-resourced physician-led models) limits widespread adoption.

The identification of Traditional-Synchronous and Asynchronous models as more acceptable than physician-led models suggests that integrating specialized genetic personnel (counselors) is crucial for quality and sustainability. Furthermore, the data underscores an urgent need for authoritative standards and reimbursement reforms to overcome operational barriers. By understanding the basis of this variability, the DCM Consortium aims to develop scalable care approaches that can be uniformly adopted across diverse healthcare settings, ultimately improving patient outcomes through precision medicine.